Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBM-007 in treatment-naïve exudative AMD
NCT04895293Phase 2Completed
- Sponsor
- Raj K. Maturi MD
- Start
- Jun 2021
- Primary completion
- Feb 2022
- Modality
- RNA Aptamers, DNA Aptamers
- Countries
- 1
01
Overview
A Phase 2 trial of umedaptanib pegol in exudative age-related macular degeneration, sponsored by Raj K. Maturi MD. Started Jun 2021; status: completed.
02
Drugs
umedaptanib pegol
03
Conditions
exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT04895293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04895293.